Occurrence of Adverse Effects With Immune Checkpoint Inhibitors Between a Single and Double Dose Regimen (ICI DODO)

University Hospital Center (CHU)

Status: Completed

Conditions: Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04956783

RECHMPL21_0298

Details and patient eligibility

About

This is a retrospective evaluation of the impact of a double dose regimen of immunotherapy use in cancer treatment compared to the single-dose regimen on the occurrence of clinically significant adverse events.

The aim of this study is to provide evidence-based arguments to help clinicians to propose the best treatment regimen for each patient.

Enrollment: 500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any adult patient with anti-PD-1 or PD-L-1 immune checkpoint inhibitor as monotherapy

Exclusion criteria

• age < 18